Evidence map›Paper›PMID 34773678›Full record

ArticleEpilepsia open2022

Different pharmacoresistance of focal epileptic spasms, generalized epileptic spasms, and generalized epileptic spasms combined with focal seizures.

Yukitoshi Takahashi, Akiko Ota, Jun Tohyama, Tomoko Kirino, Yumi Fujiwara, Chizuru Ikeda, Shigeki Tanaka, Jyunya Takahashi, Toshihiko Shinoki, Hiroshi Shiraga and 5 more

Open access · goldAbstract read
In one paragraph

Article in Epilepsia open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

Yukitoshi TakahashiNational Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.ORCID 0000-0002-1922-8967
Akiko OtaNational Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.
Jun TohyamaNHO Nishiniigata Chuo Hospital, Niigata, Japan.
Tomoko KirinoShikoku Medical Center for Children and Adults, NHO, Zentsuji, Japan.
Yumi FujiwaraShikoku Medical Center for Children and Adults, NHO, Zentsuji, Japan.
Chizuru IkedaKumamoto Saishun Medical Center, NHO, Goushi, Japan.
Shigeki TanakaNational Hospital Nagasaki Medical Center, NHO, Omura, Japan.
Jyunya TakahashiNational Mie Hospital, NHO, Tsu, Japan.
Toshihiko ShinokiNational Mie Hospital, NHO, Tsu, Japan.
Hiroshi ShiragaOkayama Medical Center, NHO, Okayama, Japan.
Takushi InoueOkayama Medical Center, NHO, Okayama, Japan.
Hiroshi FujitaNational Hospital Organization, Aomori, Aomori, Japan.
Motoki BonnoMie Chuo Medical Center, NHO, Tsu, Japan.
Masayoshi NagaoNHO Hokkaido Medical Center, Sapporo, Japan.
Hideo KanekoNagara Medical Center, NHO, Gifu, Japan.
National Mie Hospital · JPOkayama Medical Center · JPShikoku Medical Center for Children and Adults · JPKumamoto Medical Center · JPMie Chuo Medical Center · JPNagara Medical Center · JPNagasaki Medical Center · JPNational Epilepsy Center · JPNational Hospital Organization · JPNational Hospital Organization Hokkaido Medical Center · JPNishi Niigata Chuo National Hospital · JPUniversity of Shizuoka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAmong standard treatments for infantile spasms, adrenocorticotropic hormone (ACTH) is reported as the best treatment, but ACTH is ineffective in one-half of the patients. To establish precision medicine, we examined pharmacoresistance of focal epileptic spasms (ES), generalized ES, and generalized ES combined with focal seizures, diagnosed based on the revised seizure classification of ILAE in 2017.

methodsWe conducted a retrospective nationwide study in Japan on the long-term seizure outcome of ES. Long-term seizure outcome was evaluated by seizure-free rate, seizure-free period, and Kaplan-Meier curve. Seizure-free was defined as seizure control for longer than 2 months.

resultsFrom the medical history of 501 patients, 325 patients had generalized ES only (GES group) at the start of the first treatment, 125 patients had generalized ES after focal seizure onset (FS-GES group), seven patients had focal ES after focal seizure onset (FS-FES group), and 24 patients had generalized ES combined with focal seizures after focal seizure onset (FS-GES + FS group). Seizure-free period of ES (generalized ES and focal ES) [mean (95% confidence interval)] was 2.7 (0.0-5.4) months in GES group, 1.1 (0.1-2.2) months in FS-GES group, 1.0 (0.2-1.9) months in FS-GES + FS group, and 0.1 (-0.2-0.5) months in FS-FES group. Seizure-free rate, seizure-free period, and Kaplan-Meier curve of generalized ES were almost the same in GES group and FS-GES group, with characteristics of superior response to ACTH. Mean seizure-free period of generalized ES combined with focal seizures was significantly shorter in FS-GES + FS group than in GES group. Mean seizure-free period of focal ES in FS-FES group was extremely short with exceedingly early relapse. SIGNIFICANCE: Pharmacoresistance was different in generalized ES, focal ES, and generalized ES combined with focal seizures. ES with focal features or with focal seizures may have focal lesions, thus consider surgical options earlier in the course.

Indexed as

Spasms, InfantileElectroencephalographyHumansRetrospective StudiesSeizuresSpasmcombined generalized epileptic spasmsfocal epileptic spasmsgeneralized epileptic spasmsinfantile spasmsseizure outcome

Identifiers

PMID34773678
PMCPMC8886099
OpenAlexW3214477154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.